|By PR Newswire||
|April 19, 2013 08:00 AM EDT||
SEATTLE, April 19, 2013 /PRNewswire/ -- Presage Biosciences, a leader in precision oncology, today announced the initiation of a clinical trial and the first patient use of CIVO™, the company's precision oncology platform designed to improve treatment decisions for cancer patients. The single arm, non-therapeutic, observational study, being conducted at Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, is intended to evaluate the feasibility of Presage's CIVO in assessing lymphoma response to multiple microinjected candidate chemotherapy agents.
"Results from this initial study will assess the potential of CIVO to guide personalized clinical treatment for lymphoma patients," said Richard Klinghoffer, Ph.D., Vice President of Research & Development at Presage Biosciences. "CIVO is designed to enable analysis of the potential therapeutic effect of multiple drugs simultaneously following precise delivery of each agent to a distinct location on the patient's tumor. By employing this technology we hope to discern which drugs induce a localized anti-tumor response, indicative of therapeutic effect, prior to systemic administration of chemotherapy."
The trial will enroll up to 12 patients with either newly diagnosed lymphomas who have not yet received treatment or relapsed lymphoma previously treated with one or more agents in the R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Patients' lymphomas will be microinjected with up to four drugs comprising rituximab, vincristine, doxorubicin and prednisolone. Twenty-four hours later, the lymph node of interest will be removed and analyzed for target engagement and tissue response.
More information about this study, including additional eligibility criteria and contact information, can be found on clinicaltrials.gov. Study participants are not expected to benefit medically from participation or to directly benefit from the data generated in this feasibility study. None of the data will be released to the patient or treating physician in a manner that could be used to make treatment decisions. Patients may contact Jennifer Lindquist, Patient Care Coordinator / Lymphoma - Intake Office at Seattle Cancer Care Alliance, [email protected] or 206-288-6202 for more information.
"When a patient learns they have cancer, they want effective drugs that cause as little toxicity as possible. An expert panel from the American Society for Clinical Oncology found that previous attempts to predict cancer sensitivity to therapeutic agents using cancer cells grown in tissue culture dishes have not helped the way we hoped they would," said Oliver W. Press, M.D., Ph.D., a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, Professor of Medicine at the University of Washington and the Principal Investigator for the study. "Oncologists and patients are eager for a reliable method to assess cancer drug sensitivity or resistance in the patient's own tumor. We look forward to evaluating the Presage's CIVO precision oncology platform and gathering patient data to evaluate the potential of this innovative approach."
About Presage CIVO™ Precision Oncology
Presage Biosciences' patented CIVO precision oncology platform offers an entirely novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. The technology allows for the precise placement of multiple microdoses of candidate treatments through the skin and directly into a tumor. Such a controlled localization enables drug-specific responses to be measured for an array of drugs or drug combinations. These microdoses also provide the ability to analyze drug effects across the span of a living tumor thus capturing the heterogeneity of cancer cells.
About Presage Biosciences
Presage Biosciences is a leader in precision oncology. In addition to developing the CIVO™ precision oncology platform, the company is driving discovery of effective drug combinations. We are dedicated to improving cancer drug development so that patients can receive the most effective treatment possible. Presage partners with oncology-focused pharmaceutical companies through strategic alliances to provide previously inaccessible in vivo data to validate novel targets, promote drug candidates to the right indications, and discover effective drug combinations. Presage's CIVO is the world's only known technology to perform simultaneous comparisons of multiple drugs within a living tumor. Presage is privately held and based in Seattle. For more information, visit www.presagebio.com.
The project described was supported by Award Number R42CA144104 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
SOURCE Presage Biosciences
I'm a lonely sensor. I spend all day telling the world how I'm feeling, but none of the other sensors seem to care. I want to be connected. I want to build relationships with other sensors to be more useful for my human. I want my human to understand that when my friends next door are too hot for a while, I'll soon be flaming. And when all my friends go outside without me, I may be left behind. Don't just log my data; use the relationship graph. In his session at @ThingsExpo, Ryan Boyd, Engi...
Oct. 26, 2016 11:45 AM EDT Reads: 1,857
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Oct. 26, 2016 11:45 AM EDT Reads: 2,322
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
Oct. 26, 2016 11:45 AM EDT Reads: 484
Successful digital transformation requires new organizational competencies and capabilities. Research tells us that the biggest impediment to successful transformation is human; consequently, the biggest enabler is a properly skilled and empowered workforce. In the digital age, new individual and collective competencies are required. In his session at 19th Cloud Expo, Bob Newhouse, CEO and founder of Agilitiv, will draw together recent research and lessons learned from emerging and established ...
Oct. 26, 2016 11:45 AM EDT Reads: 1,508
Whether they’re located in a public, private, or hybrid cloud environment, cloud technologies are constantly evolving. While the innovation is exciting, the end mission of delivering business value and rapidly producing incremental product features is paramount. In his session at @DevOpsSummit at 19th Cloud Expo, Kiran Chitturi, CTO Architect at Sungard AS, will discuss DevOps culture, its evolution of frameworks and technologies, and how it is achieving maturity. He will also cover various st...
Oct. 26, 2016 11:30 AM EDT Reads: 2,521
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU’s GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes.
Oct. 26, 2016 11:30 AM EDT Reads: 1,756
Enterprises have been using both Big Data and virtualization for years. Until recently, however, most enterprises have not combined the two. Big Data's demands for higher levels of performance, the ability to control quality-of-service (QoS), and the ability to adhere to SLAs have kept it on bare metal, apart from the modern data center cloud. With recent technology innovations, we've seen the advantages of bare metal erode to such a degree that the enhanced flexibility and reduced costs that ...
Oct. 26, 2016 11:29 AM EDT Reads: 101
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
Oct. 26, 2016 11:00 AM EDT Reads: 3,172
Qosmos, the market leader for IP traffic classification and network intelligence technology, has announced that it will launch the Launch L7 Viewer at CloudExpo | @ThingsExpo Silicon Valley, being held November 1 – 3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The L7 Viewer is a traffic analysis tool that provides complete visibility of all network traffic that crosses a virtualized infrastructure, up to Layer 7. It facilitates and accelerates common IT tasks such as VM migra...
Oct. 26, 2016 11:00 AM EDT Reads: 215
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Oct. 26, 2016 10:30 AM EDT Reads: 1,125
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessi...
Oct. 26, 2016 10:15 AM EDT Reads: 5,166
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Oct. 26, 2016 10:15 AM EDT Reads: 4,956
operations aren’t merging to become one discipline. Nor is operations simply going away. Rather, DevOps is leading software development and operations – together with other practices such as security – to collaborate and coexist with less overhead and conflict than in the past. In his session at @DevOpsSummit at 19th Cloud Expo, Gordon Haff, Red Hat Technology Evangelist, will discuss what modern operational practices look like in a world in which applications are more loosely coupled, are deve...
Oct. 26, 2016 10:15 AM EDT Reads: 1,887
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
Oct. 26, 2016 10:00 AM EDT Reads: 2,020
In his session at 19th Cloud Expo, Nick Son, Vice President of Cyber Risk & Public Sector at Coalfire, will discuss the latest information on the FedRAMP Program. Topics will cover: FedRAMP Readiness Assessment Report (RAR). This new process is designed to streamline and accelerate the FedRAMP process from the traditional timeline by initially focusing on technical capability instead of documentation preparedness. FedRAMP for High-impact level systems. Early in 2016 FedRAMP officially publishe...
Oct. 26, 2016 10:00 AM EDT Reads: 462